For example, in order for patients to be eligible for anti-HER2 antibody therapy (e.g., trastuzumab, or pertuzumab), the HER2-positive breast cancers must have a predefined immunohistochemical score. The gene discussed is ERBB2; the disease is breast carcinoma.